Joint Development and Exclusive Sales Partnership with Eisai Co.,Ltd. for SI-613 in China
First written in FY2020. 1 of 4 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025DroppedAnnual report
「The joint development and exclusive sales agreement in China with Eisai Co., Ltd. for SI-613, a treatment for osteoarthritis, and the agreement concerning exclusive sales rights in South Korea, which had been included through the previous consolidated fiscal year, were deleted because they were terminated following the discontinuation of SI-613 development.」
Following the discontinuation of SI-613 development, the company terminated its joint development and exclusive sales agreement with Eisai Co., Ltd. in China and its exclusive sales agreement in South Korea. - FY2022SoftenedAnnual report
「For SI-613, a treatment for osteoarthritis, we entered into an agreement with Eisai Co., Ltd. covering joint development and a sales partnership in China in April 2020, followed by a sales partnership agreement in South Korea in September 2020. However, we are prioritizing investigation into the cause of the shock experienced after the launch of Joycl in Japan and the occurrence of anaphylaxis, and will consider our future development policy after assessing developments.」
For SI-613's expansion in China and South Korea, the partnership agreements had been signed, but the company prioritized investigating the cause of safety issues related to Joycl and reached the stage of assessing its future development policy. - FY2021-Q2AdvancedAnnual report
「In September 2020, we entered into an agreement with Eisai Co., Ltd. for a sales partnership in South Korea. Following the agreement with the company in April 2020 covering joint development and a sales partnership in China, this was our partnership in a second country.」
For SI-613, the partnership territory with Eisai Co., Ltd. expanded from China to South Korea. In South Korea, the company entered into an agreement concerning exclusive sales rights, making it the second country in which a partnership had been established. - FY2020First statedAnnual report
「In April 2020, we entered into an agreement with Eisai Co., Ltd. covering the joint development and sales partnership for SI-613, a treatment for osteoarthritis, in China, enabling us to advance the product's multinational development. The number of symptomatic patients with knee osteoarthritis in China is estimated at approximately 47 million, about 6 times the number in Japan, and is expected to increase further as the population ages.」
In addition to the domestic partnership with Ono Pharmaceutical Co., Ltd. for SI-613, the company entered into a joint development and exclusive sales agreement with Eisai Co., Ltd. in China, giving concrete form to the product's multinational expansion. The company expected to receive milestone-based royalties based on progress in development, sales and related activities.